Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in Transthyretin Amyloid (ATTR) Cardiomyopathy

NCT05233163 is registered in ClinicalTrials.gov with Columbia University as lead sponsor.

NCT NCT05233163
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05233163 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in Transthyretin Amyloid (ATTR) Cardiomyopathy
Lead sponsor
Columbia University
Phase
Phase 4
Overall status
Completed
Start date
March 14, 2022
Completion date
May 1, 2023
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

transthyretin amyloid cardiomyopathy